We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals

55 hedge funds and large institutions have $83.8M invested in Fennec Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $204K | Put options by funds: $65K

0% more funds holding

Funds holding: 5555 (0)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

0.16% less ownership

Funds ownership: 54.7%54.54% (-0.16%)

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

28% less capital invested

Capital invested by funds: $116M → $83.8M (-$32M)

Holders
55
Holders Change
Holders Change %
0%
% of All Funds
1.11%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
11
Increased
14
Reduced
19
Closed
11
Calls
$204K
Puts
$65K
Net Calls
+$139K
Net Calls Change
+$139K
Name Holding Trade Value Shares
Change
Change in
Stake
RJFSA
26
Raymond James Financial Services Advisors
Florida
$152K +$176K +25,000 New
Goldman Sachs
27
Goldman Sachs
New York
$150K -$40.6K -5,761 -19%
WMSA
28
Weiss Multi-Strategy Advisers
New York
$147K -$6.25K -886 -4%
PPA
29
Parametric Portfolio Associates
Washington
$146K +$70K +9,934 +70%
GCP
30
GSA Capital Partners
United Kingdom
$136K +$158K +22,385 New
AQR Capital Management
31
AQR Capital Management
Connecticut
$132K +$153K +21,759 New
TRCT
32
Tower Research Capital (TRC)
New York
$126K +$138K +19,631 +1,669%
Bank of America
33
Bank of America
North Carolina
$125K -$112K -15,851 -43%
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
$120K
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$112K -$3.57K -506 -3%
SO
36
STRS Ohio
Ohio
$93K
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$88K
Ameriprise
38
Ameriprise
Minnesota
$86K +$99.3K +14,090 New
AIG
39
American International Group
New York
$78K -$3K -425 -3%
Deutsche Bank
40
Deutsche Bank
Germany
$74K +$7.41K +1,051 +9%
Barclays
41
Barclays
United Kingdom
$60K -$15.2K -2,162 -18%
HSBC Holdings
42
HSBC Holdings
United Kingdom
$60K +$71.8K +10,183 New
JP Morgan Chase
43
JP Morgan Chase
New York
$48K +$4.98K +706 +10%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$31.6K +$31K +4,404 +544%
Legal & General Group
45
Legal & General Group
United Kingdom
$16K -$5.93K -841 -24%
AIP
46
Ameritas Investment Partners
Nebraska
$12K
MAM
47
Meeder Asset Management
Ohio
$8K
Bank of Montreal
48
Bank of Montreal
Ontario, Canada
$7K -$5.27K -748 -43%
Citigroup
49
Citigroup
New York
$6K -$13.2K -1,872 -65%
APA
50
American Portfolios Advisors
New York
$4.54K +$5.29K +750 New

FENC Hedge Fund Activity: Q3 2020 in Review

55 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2020, worth a combined $83.8M — down 28% from $116M a quarter earlier.

Fund positioning in FENC was balanced in Q3 2020: 11 funds opened new positions, 11 closed out, 14 added to existing stakes and 19 trimmed.

The largest buyer was Russell Investments Group, opening a new position worth an estimated $1.54M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.43M sold.

  • 55 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $83.8M of Fennec Pharmaceuticals stock for Q3 2020, down 28% quarter-over-quarter.
  • 11 funds opened new Fennec Pharmaceuticals positions in Q3 2020 and 11 closed out, a net change of 0 holders.
  • The largest Fennec Pharmaceuticals buyer in Q3 2020 was Russell Investments Group, an estimated $1.54M added.
  • The largest Fennec Pharmaceuticals seller in Q3 2020 was Opaleye Management, an estimated $1.43M sold.

Based on aggregated 13F filings for Q3 2020.